Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc, and Lilly USA, LLC
At least half of all people with diabetes die of cardiovascular disease (CVD), so providing care for patients with type 2 diabetes mellitus (T2DM) entails consideration of primary and possibly secondary prevention of cardiovascular (CV) conditions. CV risk factors such as obesity, hypertension, and lipid levels, in addition to the risk of hypoglycemia, must be considered when selecting antihyperglycemic therapy. Data from CV outcomes trials demonstrate beneficial CV-related health outcomes associated with some antihyperglycemic medications. Primary care clinicians are a key healthcare resource for most people with T2DM and need to be well informed on how these diabetes treatments affect glycemic control and other outcomes, including CV health.
Family physicians, nurse practitioners, physician assistants, and other primary care clinicians who provide care for patients with diabetes
At the conclusion of this activity, participants should be better able to:
Characterize the relationship between type 2 diabetes mellitus (T2DM) and its common comorbidities and complications, including cardiovascular (CV) disease
Assess current evidence related to antihyperglycemic medications and CV risk
Identify patients who may benefit from treatment plans that incorporate sodium glucose cotransporter-2 (SGLT-2) inhibitors to help achieve T2DM treatment targets and improve other health outcomes
Individualize T2DM treatment strategies with consideration for glycemic and nonglycemic parameters, such as weight, blood pressure, and other CV risk factors
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Jeff Unger, MD, ABFM, FACE Director, Unger Primary Care Concierge Medical Group Rancho Cucamonga, CA Director, Catalina Research Institute Montclair, CA
Dr. Unger reports that he receives consulting fees from GlaxoSmithKline, MedImmune, and Sanofi. Dr. Unger also serves on the speakers’ bureau for Sanofi.
Helena W. Rodbard, MD, FACP, MACE Medical Director, Endocrine and Metabolic Consultants Rockville, MD Past President, American Association of Clinical Endocrinologists Past President, American College of Endocrinology
Dr. Rodbard reports that she receives consulting fees from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc/Lilly USA, LLC, Merck, Novo Nordisk, Sanofi, and Regeneron. Dr. Rodbard also serves on the speakers’ bureaus for AstraZeneca, Merck, and Novo Nordisk and has conducted contracted research supported by AstraZeneca, Bristol-Myers Squibb, Lexicon Pharmaceuticals, Merck, Novo Nordisk, Regeneron, and Sanofi.
Salil Sethi, MD, MPH Interventional Cardiologist Freedman Memorial Cardiology Alexandria, LA
Dr. Sethi has no relevant financial relationships to disclose.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education, Boehringer Ingelheim Pharmaceuticals, Inc, or Lilly USA, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
UPDATE: Empagliflozin Indicated to Reduce Risk of CV Death
Since the recording of this enduring activity, a new development has emerged that is of interest to clinicians who provide care for patients with type 2 diabetes mellitus (T2DM). On December 2, 2016, the US Food and Drug Administration (FDA) announced its approval of an additional indication for the sodium glucose cotransporter-2 inhibitor empagliflozin.1 Based on a review of data from the EMPA-REG OUTCOME trial, which demonstrated that empagliflozin use was associated with a 38% reduction in cardiovascular (CV) death and a 32% reduction in all-cause mortality compared with placebo,2 empagliflozin is now indicated to reduce the risk of CV death in adult patients with T2DM and CV disease.
References 1. US Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes: study links Jardiance to improved survival in patients with type 2 diabetes with cardiovascular disease [news release]. Silver Spring, MD: FDA; December 2, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed December 2, 2016. 2. US Food and Drug Administration. FDA Briefing Document: Endocrine and Metabolic Drug Advisory Committee Meeting June 28, 2016. FDA website. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508422.pdf. Accessed December 2, 2016.
Hardware and Software Requirements
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required